دانلود رایگان مقاله لاتین کنترل قند خون از سایت الزویر
عنوان فارسی مقاله:
کاهش تاخیر سود و زیان، کنترل قند خون و پایبندی درمانی در دیابت نوع 2
عنوان انگلیسی مقاله:
Delay discounting of gains and losses, glycemic control and therapeutic adherence in type 2 diabetes
سال انتشار : 2016
برای دانلود رایگان مقاله کنترل قند خون اینجا کلیک نمایید.
مقدمه انگلیسی مقاله:
1. Introduction
According to the World Health Organization, only 50% of patients with chronic illness demonstrate satisfactory adherence, at best (De Geest and Sabaté, 2003). Adherence is defined as the extent to which a patient’s behavior is consistent with medical or health advice. It applies to all aspects of the treatment, including: accepting a screening, attending a consultation, taking medication as prescribed, monitoring its efficiency and changing health behavior. It is particularly essential and difficult for patients with chronic, asymptomatic diseases, for which treatment has preventive rather than curative goals and may impact quality of life (Osterberg and Blaschke, 2005). Type 2 diabetes is typically one of these diseases. In the treatment of diabetes, poor adherence has dramatic, yet delayed, consequences in terms of quality of life, complications and expenses (Lerman, 2005). The determinants of adherence have been thoroughly studied (Simon et al., 2009) but means of improving adherence are scarce and of a modest efficiency. Poor adherence might be interpreted as partially resulting from a lower value attributed to health as compared to other goals. This study is based on the hypothesis that the value of health, as any other reward, might be discounted as a function of the delay necessary to obtain this reward. Indeed, expected benefits of patients’ care are often delayed (Reach, 2008).
برای دانلود رایگان مقاله کنترل قند خون اینجا کلیک نمایید.
کلمات کلیدی:
Adherence to oral therapy for type 2 diabetes: opportunities for ... - NCBI https://www.ncbi.nlm.nih.gov/pubmed/15008033 by D Bartels - 2004 - Cited by 35 - Related articles J Am Acad Nurse Pract. 2004 Jan;16(1):8-16. Adherence to oral therapy for type 2 diabetes: opportunities for enhancing glycemic control. Bartels D(1). Adherence to Therapies in Patients with Type 2 Diabetes - NCBI - NIH https://www.ncbi.nlm.nih.gov › NCBI › Literature › PubMed Central (PMC) by LE García-Pérez - 2013 - Cited by 144 - Related articles Aug 30, 2013 - The majority of patients with type 2 diabetes fail to control glycemia with diet and exercise and require pharmacotherapy—in general, initially ... Adherence to Oral Therapy for Type 2 Diabetes: Opportunities for ... onlinelibrary.wiley.com/doi/10.1111/j.1745-7599.2004.tb00366.x/full by D Bartels - 2004 - Cited by 35 - Related articles Adherence to Oral Therapy for Type 2 Diabetes: Opportunities for Enhancing ... intervention with multiple agents to maintain adequate glycemic control. Glycemic control and adherence to basal insulin therapy in Taiwanese ... onlinelibrary.wiley.com/doi/10.1111/jdi.12532/full by MN Chien - 2016 - Cited by 3 - Related articles May 30, 2016 - A total of 836 patients with type 2 diabetes taking oral antidiabetic drugs ... study aimed to discover the glycemic control, treatment adherence, ... Glycemic control and adherence to basal insulin therapy in Taiwanese ... onlinelibrary.wiley.com/doi/10.1111/jdi.12532/abstract by MN Chien - 2016 - Cited by 3 - Related articles May 30, 2016 - Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus ... Delay discounting of gains and losses, glycemic control and ... https://www.researchgate.net/.../308390267_Delay_discounting_of_gains_and_losses_gl... Nov 1, 2016 - ... 4 of the authors on ResearchGate · Delay discounting of gains and losses, glycemic control and therapeutic adherence in type 2 diabetes. Delay discounting of gains and losses, glycemic control and ... www.sciencedirect.com/science/article/pii/S0376635716302534 by G Lebeau - 2016 - Cited by 1 - Related articles Delay discounting of gains and losses, glycemic control and therapeutic adherence in type 2 diabetes. Gaële Lebeau,,, , ,; Silla M. Consoli,,; Raphael Le Bouc,,, ...
